Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams acquired 10,878 shares of the company’s stock in a transaction on Wednesday, September 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $21,320.88. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

  • On Monday, September 24th, Gregg Williams acquired 15,520 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.86 per share, with a total value of $28,867.20.
  • On Friday, September 21st, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.80 per share, with a total value of $28,575.00.
  • On Wednesday, September 19th, Gregg Williams acquired 29,616 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.82 per share, with a total value of $53,901.12.
  • On Monday, September 17th, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.79 per share, with a total value of $28,416.25.
  • On Thursday, September 13th, Gregg Williams acquired 31,750 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.65 per share, with a total value of $52,387.50.
  • On Tuesday, September 11th, Gregg Williams acquired 26,483 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.68 per share, with a total value of $44,491.44.
  • On Friday, September 7th, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.73 per share, with a total value of $27,463.75.
  • On Wednesday, September 5th, Gregg Williams purchased 30,828 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $52,099.32.
  • On Friday, August 31st, Gregg Williams purchased 31,750 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.72 per share, with a total value of $54,610.00.
  • On Wednesday, August 29th, Gregg Williams purchased 15,720 shares of Second Sight Medical Products stock. The stock was acquired at an average cost of $1.61 per share, with a total value of $25,309.20.

Shares of NASDAQ:EYES traded down $0.10 during trading on Thursday, reaching $1.87. The company’s stock had a trading volume of 226,800 shares, compared to its average volume of 402,599. Second Sight Medical Products Inc has a 12 month low of $1.05 and a 12 month high of $2.58. The company has a market cap of $130.13 million, a price-to-earnings ratio of -3.30 and a beta of 3.09.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative net margin of 418.82% and a negative return on equity of 432.45%. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. equities research analysts predict that Second Sight Medical Products Inc will post -0.58 earnings per share for the current fiscal year.

EYES has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. HC Wainwright set a $5.00 price target on shares of Second Sight Medical Products and gave the company a “buy” rating in a report on Wednesday, August 8th.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Featured Article: Earnings Per Share (EPS) Explained

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.